Prognostic Value of MRI‐Derived Apparent Diffusion Coefficient in Intermediate‐Risk Prostate Cancer Treated With Definitive Radiotherapy
The Prostate · 2026-12 · 86 (16) · 1612-1620
DOI: 10.1002/pros.70249 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, online erschienen am 13.09.2026. Verfasst von Cem Onal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University Faculty of Medicine, Adana, Turkiye. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Diffusion Magnetic Resonance Imaging. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Intermediate‐risk prostate cancer (IR‐PCa) is a heterogeneous disease with variable clinical outcomes despite established risk classification. We evaluated whether pretreatment tumor apparent diffusion coefficient (ADC) derived from multiparametric MRI was associated with long‐term outcomes and provided additional prognostic information beyond established clinical risk classification in patients treated with definitive radiotherapy. Methods and Materials We retrospectively analyzed 238 patients with IR‐PCa treated with definitive radiotherapy. Tumor ADC values were obtained from pre‐treatment diffusion‐weighted MRI. Patients were stratified according to ADC levels and clinical risk subgroups, including favorable and unfavorable intermediate‐risk disease. Survival analyses and Cox regression models were used to assess associations between ADC and clinical outcomes, including biochemical failure and distant metastasis.
Results
At a median follow‐up of 10.3 years, 22 patients developed biochemical failure, and 12 developed distant metastases. Lower ADC values (≤ 0.668 × 10 −3 mm 2 /s) were associated with inferior outcomes, with a significant impact on freedom from distant metastasis (FFDM) (HR 3.94, 95% CI 1.14–13.62; p = 0.03). When ADC was combined with clinical risk classification, outcomes differed across the four resulting subgroups for both FFDM ( p = 0.02) and FFBF ( p = 0.02). However, the FIR–low ADC subgroup included only seven patients, and these subgroup findings should be considered exploratory.
Conclusions
Lower tumor ADC was associated with an increased risk of distant metastasis and provided exploratory prognostic information beyond established clinical risk classification. Given the limited number of events and the data‐derived cutoff, these findings require external validation before ADC can be used to guide treatment selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University Faculty of Medicine, Adana, Turkiye.
- Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkiye.
- Department of Radiology, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University Faculty of Medicine, Adana, Turkiye.
- Division of Radiation Oncology, Iskenderun Gelisim Hospital, Hatay, Turkiye.
ORCID-Profile: Cem Onal, Gurcan Erbay, Aysenur Elmali, Birhan Demirhan, Ozan Cem Guler
Zitieren
APA
Onal, C., Erbay, G., Elmali, A., Demirhan, B., & Guler, O. C. (2026). Prognostic Value of MRI‐Derived Apparent Diffusion Coefficient in Intermediate‐Risk Prostate Cancer Treated With Definitive Radiotherapy. The Prostate, 86(16), 1612-1620. https://doi.org/10.1002/pros.70249
Vancouver
Onal C, Erbay G, Elmali A, Demirhan B, Guler OC. Prognostic Value of MRI‐Derived Apparent Diffusion Coefficient in Intermediate‐Risk Prostate Cancer Treated With Definitive Radiotherapy. The Prostate. 2026;86(16):1612-1620. doi:10.1002/pros.70249
BibTeX
@article{Onal2026,
author = {Onal, Cem and Erbay, Gurcan and Elmali, Aysenur and Demirhan, Birhan and Guler, Ozan Cem},
title = {Prognostic Value of MRI‐Derived Apparent Diffusion Coefficient in Intermediate‐Risk Prostate Cancer Treated With Definitive Radiotherapy},
journal = {The Prostate},
year = {2026},
volume = {86},
number = {16},
pages = {1612--1620},
doi = {10.1002/pros.70249}
}
EUVIMED